Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
|Articles|November 2, 2021
CDC Finds mRNA COVID-19 Vaccines Provide More Immunity Than Prior Infection
Author(s)Ashley Gallagher, Editor
The results also showed they were nearly 20 times more effective at preventing hospitalizations from the virus for individuals older than 65 than a prior infection alone.
Advertisement
The results from a CDC study show that mRNA COVID-19 vaccines are associated with significantly more immunity than a prior COVID-19 infection.
“[These] data provides powerful evidence that vaccinations offer superior protection against COVID-19 than relying on natural immunity alone,” Shaun Grannis, MD, professor of family medicine at Indiana University School of Medicine, said in a statement.
Overall, those who were unvaccinated with a prior COVID-19 infection were 5 times more likely to be hospitalized from COVID-19 than those who were vaccinated.
The investigators analyzed the number of unvaccinated individuals who tested positive for COVID-19 more than 3 months before hospitalization from COVID-19 and those who were vaccinated with either the Moderna or Pfizer vaccine and were not diagnosed with COVID-19 prior to hospitalization.
Investigators from the CDC’s VISION Network gathered data for 7000 who fit the criteria of the study in 9 different states.
The results also showed that mRNA vaccines were nearly 20 times more effective at preventing hospitalizations from COVID-19 for individuals older than aged 65 years than a prior infection alone.
Reference
COVID vaccines 5 times more effective at preventing COVID-related hospitalization than prior infection alone. EurekAlert. News release. October 29, 2021. Accessed November 1, 2021.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
Pharmacists can explain the evidence supporting the intramuscular injection, address specific concerns, and help families understand what is known—and what is not known—about oral vitamin K.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Semaglutide Normalized Liver Fat in Most Adults With Obesity
2
Reframing Statins and Brain Health Around Stroke Prevention
3
Phase 3 Trial Finds Adding Monoclonal Antibody to mRNA Vaccine Improves COVID-19 Immunization Tolerability
4
mRNA Reenters the Mainstream
5